Skip to content
Research Article Open access CC BY 4.0

Mucormycosis in COVID-19 Pandemic: Study Involving Tertiary Hospitals in Aurangabad District, India

Pooja Muley, Himanshu Gupta, Abha Gupta

Asian Journal of Research in Infectious Diseases · pp. 8–17 · Published 5 Jul 2023

10.9734/ajrid/2023/v14i1277

Abstract

Introduction: An abrupt increase in the mucormycosis patients in india during the COVID 19 pandemic was observed. A collective study was conducted in tertiary care hospitals in Aurangabad. Materials and Methods: A retrospective descriptive study was conducted in Aurangabad (Maharashtra), in association with the Aurangabad Municipal Corporation (AMC), oralcare.co.in and SNDH Hospital, Aurangabad. Data was collected by AMC from 3 major tertiary hospitals present in Aurangabad where treatment of Mucormycosis was done from May 2021 to July 2021. The data of total 135 patients with Mucormycosis was received by the AMC were included in the study. It included demographics of the patients, medical and clinical history, history of COVID 19, treatment of COVID 19, type of Mucormycosis, treatment and outcomes of Mucormycosis. Results: In the present study, 74.7% of Mucormycosis patients were males. 77.4% of Mucormycosis patients were above 50 years of age. It was seen that about 67% of patients with Mucormycosis had diabetes mellitus as the most common risk factor. About 87.4% of patients had a history of COVID-19. Majority of the patients in the study population were diagnosed with the rhino-maxillary-orbital type of Mucormycosis which is 39%, followed by the rhino-cerebral type-25%. Only 1% patients showed rhiono-nasal -orbital type of Mucormycosis. 30% patients were not categorised into any type. All the patients in the study population received amphotericin B and surgical treatment. About 84.4% patients were discharged after the Mucormycosis treatment. 15.6% patients died during or after the treatment. Conclusion: Mucormycosis was predominantly seen in male above the age of 50 years, COVID-19 infection and diabetes mellitus was common risk factor for Mucormycosis.

COVID-19 mucormycosis rhino-cerebroorbital diabetes health care systems

References (31)

  1. 1 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [DOI]
  2. 2 Home visits: a strategy to improve newborn survival - Authors' reply [DOI]
  3. 3 Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 [DOI]
  4. 4 Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases [DOI]
  5. 5 Epidemiology and Clinical Manifestations of Mucormycosis [DOI]
  6. 6 Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India [DOI]
  7. 7 The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports [DOI]
  8. 8 Epidemiology and Diagnosis of Mucormycosis: An Update [DOI]
  9. 9 Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature [DOI]
  10. 10 When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis [DOI]
  11. 11 Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection [DOI]
  12. 12 The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries
  13. 13 The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus [DOI]
  14. 14 SARS-CoV-2, Uncontrolled Diabetes and Corticosteroids—An Unholy Trinity in Invasive Fungal Infections of the Maxillofacial Region? A Retrospective, Multi-centric Analysis [DOI]
  15. 15 Ten Years' Experience in Zygomycosis at a Tertiary Care Centre in India [DOI]
  16. 16 Invasive zygomycosis in India: experience in a tertiary care hospital [DOI]
  17. 17 Rhinocerebral mucormycosis: pathways of spread [DOI]
  18. 18 Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World [DOI]
  19. 19 COVID-19 and mucormycosis superinfection: the perfect storm [DOI]
  20. 20 Rhinocerebral Mucormycosis and COVID-19 Pneumonia [DOI]
  21. 21 The Impact of COVID-19 on Blood Glucose: A Systematic Review and Meta-Analysis [DOI]
  22. 22 Imaging features of rhinocerebral mucormycosis: A study of 43 patients [DOI]
  23. 23 COVID-19 associated mucormycosis (CAM) in India: a formidable challenge [DOI]
  24. 24 Epidemiology and Antifungal Susceptibilities of Mucoralean Fungi in Clinical Samples from the United States [DOI]
  25. 25 Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach [DOI]
  26. 26 Mucormycosis in a Tertiary Care Center in South India: A 4-Year Experience [DOI]
  27. 27 Mucormycosis: A Brief Review [DOI]
  28. 28 Mucormycosis in COVID-19 pandemic: study at tertiary hospital in India [DOI]
  29. 29 Misfortune Never Comes Alone -The New "Black Fungus" Accompanying COVID-19 Wave [DOI]
  30. 30 Mucormycosis: A new threat to Coronavirus disease 2019 with special emphasis on India [DOI]
  31. 31 Coronavirus disease-associated mucormycosis (CAM): A case control study during the outbreak in India.

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

72

Page views

0

PDF downloads

44

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.